High-resolution (effectively 3-D) drug concentration measurements in tissues

Dear All: 

I’m really not trying to flood your inbox with email, but when ideas surface I do like to pass them on.

As an instructive follow-on to the email earlier this week about continuous in vivo measurements of drug concentrations, David Perlin made me aware of a use of MALDI that I’d not previously considered. Called MALDI-MSI (matrix-assisted laser desorption/ionization mass spectrometric imaging), the idea is that the MALDI technology is used to scan across a tissue slice. Data collected at each x-y location are assembled to produce a heatmap for ionization signals that have been shown to correspond to the desired analyte.

As an example of this, David’s group just published a paper in AAC (Zhao et al., doi:10.1128/AAC.01009-17) in which they used this technique to look at the distribution of echinocandins in experimental candidiasis. Here’s a pair of images from the paper: At top you have the heatmap for the candin (red = more) and at bottom a view of a corresponding H&E stain. Clever!​

This technique has been used in cancer and TB (see additional citations just below my signature). There’s even a society dedicated to this technology. I look forward to seeing additional uses of technique … we’ve long wanted to have a better understanding of PK-PD at tissue sites and this tool certainly creates new possibilities.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Some additional papers using this idea
Spatial distribution of veliparib measured by matrix-assisted laser desorption ionization mass spectrometry in triple-negative breast cancertumors.
Prideaux B, Hann B, Krings G, Coppe JP, Brown Swigart L, Lee EP, Esserman L, Yee D, Wolf D, Savic RM. J Clin Oncol. 2014 Sep 10;32(26_suppl):161.

The association between sterilizing activity and drug distribution into tuberculosis lesions.
Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O’Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE 3rd, Dartois V. Nat Med. 2015 Oct;21(10):1223-7.

Upcoming meetings of interest to the AMR community:

Share

WHO Bacterial Priority Pathogen List (PPL): 2024 update

Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO 2024 PPL. WHO’s webpage about the 2024 PPL. A PowerPoint (.pptx) deck (and there is also a .pdf version) summarizing the new PPL and all prior PPLs. 22 May 2024 post-newsletter

Environmental, Animal, and Human Uses of Phage: WHO webinars

Dear All, I have just this weekend learned of a 3-part WHO webinar series on uses of phage. Two of the webinars have already been held; the 3rd is scheduled for 16 May. All are / will be available for post-webinar review. The links you need are below — in addition, a copy of the

New UK 5-year AMR plan: Subscription model details!

Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are

ESCMID’s UNGA 2024 Petition to EU Health Ministers: Sign and Send!

Dear All, During the GLG AMR (Global Leaders Group for AMR) event just before ECCMID (see the 3 May 2024 newsletter entitled “Path To UNGA 2024 As Of 3 May 24 / Events On 14-15 May (DC, NYC)” for details), ESCMID leadership announced that ESCMID had developed a petition to be sent by and from the

Scroll to Top